2015 a record-breaking year for US venture capital funding of biotech

The USA’s Biotechnology Innovation Organization (BIO) has released a new report -  Emerging Therapeutic Company Investment and Deal Trends – highlighting ten years (2006-2015) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions.

The report also offers clinical pipeline snapshots to provide context on the degree of industry partnering and the contribution of emerging companies.

“Investment and licensing are the lifeblood of today’s emerging biotechnology companies searching for cures and treatments for patients suffering from devastating and life-threatening diseases,” said Cartier Esham, executive vice president, emerging companies, adding: “This data will deepen our understanding of investor behavior and deal making trends, a critical consideration for those seeking to encourage medical innovation and unleash the full potential for biotechnology for patients in need of new treatment options.”